Quanterix Appoints Vandana Sriram as Chief Financial Officer
August 09 2023 - 8:30AM
Business Wire
Quanterix Corporation (NASDAQ: QTRX), a company fueling
scientific discovery and breakthrough diagnostics through
ultrasensitive biomarker detection, today announced that it has
appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO),
effective August 21, 2023. Sriram replaces Michael Doyle, who has
served as the Company’s CFO since July 2021. As previously
announced, Mike will transition to the role of Executive Director,
Finance, focusing on strategic growth programs until his retirement
in March 2024.
“Vandana is experienced in developing and executing strategic
roadmaps and financial plans to foster growth opportunities,” said
Masoud Toloue, CEO at Quanterix. “The executive team and I are
thrilled to welcome her as a partner to further strengthen our
current market position and build robust scale. I would like to
thank Mike for his guidance and partnership over the last year as
we kicked off and continue to successfully execute a major
corporate transformation. I expect a smooth transition between Mike
and Vandana, and I look forward to them working together into
2024.”
Sriram is a global senior executive with more than 20 years of
diversified experience supporting the growth of high-tech
manufacturing industries through financial strategy and
transformation. Most recently, Sriram served as Senior Vice
President of Global Finance at Azenta Life Sciences where she was
responsible for the Controllership, FP&A and segment CFO
activities as a member of the leadership team. She was instrumental
in the separation of Azenta and Brooks Automation and the
subsequent deployment of capital to three acquisitions within eight
months and management of their integration processes. Prior to
Azenta, Sriram served as Senior Executive and Head of FP&A for
GE Aviation, a leading provider of commercial and military jet
engines and components. While there, she led overall financial
planning and drove simplification of financial processes and
operating rhythms during a highly dynamic COVID downturn period.
Throughout her career with GE spanning over 20 years, and at Azenta
for two years, she has partnered with operating teams to drive
engagement and accountability on financial performance, resulting
in more focused operational actions and outcomes.
“I look forward to applying my career experience in financial
management and business strategy to a company that is driving
innovation in medicine and breaking new ground in the field of
scientific research,” said Sriram. “I have great respect for the
market momentum Quanterix has created through its Simoa technology
for breakthrough discovery in research and clinical applications,
and I look forward to building on this foundation for continued
growth.”
Sriram brings global experience to Quanterix through her
previous roles at GE Additive in Germany, GE Global Growth
Organization MENAT (Middle East, North Africa and Turkey) in Dubai,
GE Capital India and Arthur Andersen in New Delhi. She is a
Chartered Accountant from the Institute of Chartered Accountants of
India. Sriram also graduated from the GE Experience Financial
Leadership Program and is a registered CPA.
To learn more about Quanterix, visit:
www.quanterix.com/about.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive
biomarker detection is fueling breakthroughs only made possible
through its unparalleled sensitivity and flexibility. The Company’s
Simoa® technology has delivered the gold standard for earlier
biomarker detection in blood, serum or plasma, with the ability to
quantify proteins that are far lower than the Limit of
Quantification (LoQ) of conventional analog methods. Its
industry-leading precision instruments, digital immunoassay
technology and CLIA-certified Accelerator laboratory have supported
research that advances disease understanding and management in
neurology, oncology, immunology, cardiology and infectious disease.
Quanterix has been a trusted partner of the scientific community
for nearly two decades, powering research published in more than
2,000 peer-reviewed journals. Find additional information about the
Billerica, Massachusetts-based company at https://www.quanterix.com
or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on
Quanterix’s expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’s actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Quanterix’s filings with the U.S. Securities and Exchange
Commission, including the “Risk Factors” sections contained
therein. Except as required by law, Quanterix assumes no obligation
to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230809302498/en/
Media: Maya Nimnicht, PAN Communications (510) 334-6273
pan.quanterix@pancomm.com Investor Relations: Ed Joyce,
Quanterix (610) 306-9917 ejoyce@quanterix.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Apr 2023 to Apr 2024